Cargando…

Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019

IMPORTANCE: The introduction of biosimilars and novel delivery devices between 2014 and 2019 may have changed the utilization of granulocyte colony-stimulating factors (G-CSF). OBJECTIVE: To assess utilization trends of G-CSFs for primary prophylaxis of febrile neutropenia (FN) among patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ching-Yu, Heldermon, Coy D., Vouri, Scott M., Park, Haesuk, Wheeler, Sarah E., Ramnaraign, Brian Hemendra, Dang, Nam Hoang, Brown, Joshua D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611485/ https://www.ncbi.nlm.nih.gov/pubmed/34812849 http://dx.doi.org/10.1001/jamanetworkopen.2021.33474

Ejemplares similares

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population
por: Wang, Ching-Yu, et al.
Publicado: (2022)

Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study
por: Wang, Ching-Yu, et al.
Publicado: (2023)

Economic Burden of Sanfilippo Syndrome in the United States
por: Ashby, Frederick, et al.
Publicado: (2023)

Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
por: Eplin, Dwight D., et al.
Publicado: (2019)

Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
por: McCoy, Rozalina G., et al.
Publicado: (2021)

Biosimilar granulocyte–colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?
por: Bonig, Halvard, et al.
Publicado: (2015)

Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage
por: Barsky, Benjamin A., et al.
Publicado: (2022)

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
por: Sandhaus, Robert, et al.
Publicado: (2020)

Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage
por: Everhart, Alexander, et al.
Publicado: (2021)

Analysis of Prescriptions Dispensed After Death and Associated Medicare Spending Following Reimbursement Policy Changes in Medicare
por: Vouri, Scott M., et al.
Publicado: (2023)

FRI528 Trends And Components Of Thyroid Status Evaluation In Commercially Insured Adults In The US, 2006-2020
por: Morris, Earl J, et al.
Publicado: (2023)

Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework
por: Wang, Weijia, et al.
Publicado: (2021)

Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product
por: Mendelsohn, Aaron B., et al.
Publicado: (2021)

Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2018)

Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009
por: Dalal, Anand A, et al.
Publicado: (2011)

More surgery in December among US patients with commercial insurance is offset by unrelated but lesser surgery among patients with Medicare insurance
por: Dexter, Franklin, et al.
Publicado: (2022)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis
por: Smoyer-Tomic, Karen E, et al.
Publicado: (2012)

Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
por: DiStefano, Michael J., et al.
Publicado: (2023)

Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008–2017
por: Desai, Raj, et al.
Publicado: (2020)

Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients
por: Dean, Emma Boswell, et al.
Publicado: (2021)

Granulocyte Colony-Stimulating Factor in Amniotic Fluid
por: Raynor, B. Denise, et al.
Publicado: (1995)

The importance of the granulocyte-colony stimulating factor in oncology
por: CETEAN, SÎNZIANA, et al.
Publicado: (2015)

Granulocyte Colony-stimulating Factor-associated Aortitis
por: Nishioka, Hiroaki, et al.
Publicado: (2023)

Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
por: Kelly, S, et al.
Publicado: (2009)

915 Is a hospital's surgical site infection rate among Medicare-insured patients a good indicator of outcome for commercially-insured patients?
por: Calderwood, Michael S., et al.
Publicado: (2014)

The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid
por: Jacobson, Jed J, et al.
Publicado: (2012)

Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers
por: Lin, Dora H., et al.
Publicado: (2018)

Medical Claim Cost Impact of Improved Diabetes Control for Medicare and Commercially Insured Patients with Type 2 Diabetes
por: Fitch, Kathryn, et al.
Publicado: (2013)

HIV Testing Trends Among Persons with Commercial Insurance or Medicaid — United States, 2014–2019
por: Henny, Kirk D., et al.
Publicado: (2021)

Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018
por: Alpern, Jonathan D., et al.
Publicado: (2022)

In vitro Colony Forming Cells and Colony Stimulating Factor in Chronic Granulocytic Leukaemia
por: Goldman, J. M., et al.
Publicado: (1974)

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis
por: Bo, Lulong, et al.
Publicado: (2011)

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
por: Hussaini, S. M. Qasim, et al.
Publicado: (2022)

Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018
por: Qian, Jingjing
Publicado: (2021)

Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
por: Benedict, Kaitlin, et al.
Publicado: (2020)

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan
por: Yoshimura, Hideaki, et al.
Publicado: (2017)

Granulocyte-colony stimulating factor producing rectal cancer
por: Takahashi, Hiroki, et al.
Publicado: (2008)

Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease
por: Barber, Robert C., et al.
Publicado: (2012)

Role of granulocyte colony-stimulating factor in human reproduction
por: Eftekhar, Maryam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q2f8p98mbcjnqisr6sllilc8s9